Select region:

Clinical trials located in

Leuven

Leuven city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Leuven, a historic city in Belgium, is renowned for its vibrant culture and rich heritage. Home to the oldest Catholic university in the world, the University of Leuven, founded in 1425, it’s a hub of academic excellence. The city boasts the 15th-century Town Hall, an architectural masterpiece with its ornate Gothic facade. Leuven is also famous for its beer culture, being the birthplace of several renowned breweries, including Stella Artois. The M-Museum Leuven adds a contemporary touch, showcasing modern art within its striking design.

  • CT-EU-00111838

    Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    BelgiumFranceGermanyItalyNetherlandsUnited Kingdom
  • Robotic-Assisted tPA Injection for Subretinal Hemorrhage Treatment

    The **RoTIS study** is an innovative research project aimed at improving the treatment for patients suffering from **subretinal hemorrhage**, a condition often associated with **age-related macular degeneration**. This condition can lead to a significant decrease in vision due to bleeding underneath the retina. Traditionally, treatments have involved manually injecting medication into the affected area to help clear the hemorrhage. However, this study introduces a cutting-edge approach by utilizing a **robotic stabilizer** to assist in the precise and stable injection of a medication called **tPA** directly into the subretinal space.

    During the surgery, which is part of your standard care, the surgeon will use a very thin needle, guided by a robot, to inject the tPA. This method aims to form a small bubble (bleb) in the subretinal space, helping to manage the hemorrhage more effectively. The goal is to ensure that the needle is placed accurately and remains stable for up to three minutes to allow for optimal treatment delivery.

    What makes this study particularly unique is the use of a **robotic stabilizer**. This tool is designed to reduce any tremors from the surgeon’s hand, ensuring the needle is precisely positioned and remains still during the injection. This level of precision is crucial, especially when dealing with delicate structures in the eye.

    Throughout the procedure, the surgical area will be closely monitored using a special type of imaging technology (**iOCT**) integrated into the surgical microscope. This allows the surgeon and the research team to observe the formation of the bleb in real-time, ensuring the treatment is delivered as intended.

    The **RoTIS study** represents a significant advancement in the treatment of subretinal hemorrhage, potentially offering patients a more effective and less invasive option. By participating in this study, you will be at the forefront of medical innovation, contributing to the development of new treatments that could benefit many people in the future.

    Belgium
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Extended safety study for participants using spartalizumab alone or combined

    This study relates to a type of medication called spartalizumab. The goal is to find out if this medicine, when given alone or with other treatments, is safe and doesn’t cause any unwanted side effects. The study is open to people who have already been involved in past studies for spartalizumab. The reason for this is to keep giving these people access to the treatment while also continuously assessing its safety.

    BelgiumCzechiaGermanyItalySpain
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Advanced endometrial cancer treatment with acasunlimab and pembrolizumab

    In this trial, scientists are trying out a new treatment for advanced endometrial cancer. This treatment involves using a combination of two drugs, acasunlimab (also referred to as GEN1046) and pembrolizumab, to fight the cancer. The study aims to see how well this treatment works and what side effects might happen. Patients taking part in the trial will be divided into two groups and will be given the trial treatment for up to two years. The total time for which each patient will be monitored is about three years. The treatment’s success will be measured by counting how many patients see their cancer shrink or go away for a period of time. Doctors will be closely watching what happens from the first day of the treatment, tracking how the tumours change and noting down any unusual health happenings that could be related to the trial.

    BelgiumDenmarkSpain
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Treatment of lung cancer before and after surgery using various drug combinations

    The NeoCOAST-2 trial is a phase II study evaluating various combinations of anticancer therapies in patients with resectable early-stage non-small cell lung cancer. This study is divided into two stages. The first stage occurs before surgery (neoadjuvant treatment), the next stage after surgery (adjuvant treatment). Researchers will use a drug called Durvalumab, which will be combined with various drugs. The goal is to determine the safety and effectiveness of these regimens for treating early-stage lung cancer, potentially improving treatment outcomes.

    The first group of patients will receive Oleclumab, Durvalumab and a strong drug – Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin. After surgery, they will be given Oleclumab and Durvalumab.

    Patients in the second group will receive Monalizumab, Durvalumab and drugs combined with platinum before surgery. After surgery, they will be given Monalizumab and Durvalumab.

    In the third group, MEDI5752 and drugs combined with platinum are administered before surgery. After surgery, patients will only receive MEDI5752.

    People from group four receive Dato-DXd, Durvalumab, Carboplatin or Cisplatin before surgery. After surgery, they will be given Durvalumab.

    Participants in the fifth group will receive AZD0171, Durvalumab and platinum doublet chemotherapy before surgery. After surgery, patients will receive AZD0171 and Durvalumab.

    BelgiumFranceHungaryItalyPortugalSpain
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing a new inhaled drug for pulmonary arterial hypertension

    This study focuses on the efficiency and safety of a new inhaled drug – MK-5475 – for patients suffering from Pulmonary Arterial Hypertension (PAH). The study is divided into two parts: phase 2 and phase 3. In phase 2, the researchers will compare three different doses of MK-5475 with a placebo over a base period of 12 weeks. The goal is to find out if any of the doses can decrease the patient’s pulmonary vascular resistance (PVR), which is the resistance that the heart must overcome to pump blood through the lungs. In Phase 3 of the study, the best performing dose from Phase 2 will be used to confirm its long-term effectiveness, safety, and tolerability over a 12-week base period with a follow-up period of up to five years. The focus is to see if this dose is better than a placebo in improving the patient’s walking distance over 6 minutes. The study aims at improving the quality of life and physical health of PAH patients with the help of the new drug.

    BelgiumFranceGermanyItalyPolandSwedenUnited Kingdom
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    BelgiumCzechiaFranceGermanyItalyPolandSpain
  • Study on sonrotoclax’s effects on returning mantle cell lymphoma

    In this medical trial, doctors are studying the effects of a medication, sonrotoclax (BGB-11417), on people suffering from a type of hard-to-treat blood cancer known as mantle cell lymphoma, which has come back or has not responded to previous treatments. The study is divided into two sections. In the first part, doctors will focus on finding how safe and tolerable this new drug is, the highest dose one can safely take, and the best dose for phase 2 studies. In the second part, they will study how effectively this medicine can treat the cancer at the best dose found in part one. The trial offers hope for better outcomes by exploring this new therapy option, aiming to improve the quality of life for patients facing this challenging condition.

    BelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • Testing sotatercept with regular treatment in severe pulmonary arterial hypertension patients

    This investigation seeks to assess the effect of a new drug named Sotatercept on people who are suffering from a serious lung disease called ‘Pulmonary Arterial Hypertension’ (PAH). The trial is intended for individuals with high-risk PAH who are facing significant danger of death. The main goal is to find out if incorporating Sotatercept into the standard treatment can improve outcomes and potentially enhance the chances of survival. Participants who enroll will receive either Sotatercept in addition to their current medication or a placebo alongside their regular treatment.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Study on effective dose of new potential drug for Leukemia or myelodysplastic syndrome treatment

    In this study, patients with a type of blood cancer, either Acute Myeloid Leukemia or Myelodysplastic Syndrome that has recurred or not responded to previous treatment, will be administered a new drug named CYAD-02. The initial phase of the study aims to determine the safe dosage of CYAD-02 for patients. Before receiving CYAD-02, patients will undergo a milder form of chemotherapy termed non-myeloablative preconditioning.

    The testing process is divided into three stages, each involving different doses of CYAD-02. The first CYAD-02 treatment will be administered after three consecutive days of chemotherapy. For patients showing stability, additional CYAD-02 treatments may be provided without preceding light chemotherapy. All patients who have received at least one CYAD-02 treatment will be monitored for approximately 15 years.

    Belgium
  • Testing combination therapy for Colorectal Cancer treatment

    The research investigates a treatment for a specific type of colon cancer using a drug combination: one is called nanrilkefusp alfa (known as SOT101), and the other is cetuximab. The primary goal is to understand the effectiveness of these drugs in combating the cancer and to ensure their safety. The research team will monitor and assess any issues that arise or worsen after the administration of the drugs. Various tests, including blood and urine tests, will be conducted to study the participants’ general health. Vital signs, such as blood pressure, body temperature, and heartbeat, will also be closely monitored. Any serious side effects that cannot be quickly addressed will be carefully reviewed.

    BelgiumCzechiaFranceItalySpain
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    BelgiumDenmarkGermanyItalyNorwayPolandSpainUnited Kingdom

See more clinical trials in other cities in Belgium:

.